Autoimmune haemolytic anaemia (AIHA) is characterized by an increased destruction of red blood cells due to immune dysfunction and auto-antibody production. Clinical manifestations are mainly related to anaemia, which can become life-threatening in case of acute haemolysis. Aiming at counterbalancing severe anaemia, supportive treatments for these patients frequently include transfusions. Unfortunately, free serum auto-antibodies greatly interfere in pre-transfusion testing, and the identification of compatible red blood cell units for AIHA patients can be challenging or even impossible. Problems faced in pre-transfusion testing often lead to delay or abandonment of transfusions for AIHA patients. In this review, we discuss publications concerning global transfusion management in AIHA, with a focus on pre-transfusion testing, and practical clues to manage the selection of transfusion units for these patients. Depending on the degree of transfusion emergency, we propose an algorithm for the selection and laboratory testing of units to be transfused to AIHA patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/vox.13699 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Analysis of the current status of red blood cell transfusion in very preterm infants from Chinese Neonatal Network in 2022].
Zhonghua Er Ke Za Zhi
January 2025
Division of Neonatology and Center for Newborn Care, Guangzhou Women and Children's Medical Center, Guangzhou510623, China.
To analyze the current status of red blood cell transfusion in very preterm infants (VPI) (gestational age at birth <32 weeks) from Chinese Neonatal Network (CHNN) in 2022. This cross-sectional study was based on the CHNN VPI cohort. It included 6 985 VPI admitted to CHNN 89 participating centers within 24 hours after birth in 2022.
View Article and Find Full Text PDFErythrocyte Alloimmunization and Autoimmunization in the Pediatric Population: A Multicenter, Cross-Sectional Study in Central China.
Transfus Med Hemother
December 2024
Department of Blood Transfusion, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Background: Erythrocyte alloantibodies and autoantibodies complicate transfusion. However, the prevalence of erythrocyte alloimmunization and autoimmunization has not been estimated in the Chinese pediatric population. Therefore, we investigated the prevalence of erythrocyte alloimmunization and autoimmunization in the Chinese pediatric population with the aim of developing a reasonable transfusion management policy in children from China.
View Article and Find Full Text PDFHow do we transfuse children in Italy? Results of a national survey.
Blood Transfus
November 2024
Transfusion Medicine Unit, Giuliano Isontina University Hospital, Trieste, Italy.
Background: Adherence to optimal practices in the preparation and issuance of pediatric blood components can significantly influence patient care outcomes. This study aims to examine the blood banking procedures across prominent Italian children's hospitals, with the goal of identifying both consistent and potentially divergent standards within this field.
Materials And Methods: A survey was conducted among the blood banks affiliated with the Italian Association of Pediatric Hospitals.
Massive transfusion of incompatible red blood cells: A case report demonstrating the benefits of a regional patient alloantibody registry and prompt automated red cell exchange.
Transfusion
December 2024
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
Article Synopsis
- Emergent transfusion can lead to serious complications like hemolysis, especially when red blood cells are incompatible with a patient’s known antibody profile.
- A 77-year-old woman who experienced significant hemorrhage received transfusions without standard testing and was later found to have multiple incompatible antibodies, highlighting the risks.
- Successful treatment of her transfusion-related hemolysis was achieved through automated red cell exchange, demonstrating the importance of having access to an alloantibody registry for timely intervention.
A Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India.
Indian J Hematol Blood Transfus
October 2024
Department of Transfusion Medicine, Tata Medical Center, Newtown, Rajarhat, 700160 Kolkata, India.
Unlabelled: The aim of this study is to analyze the profile of patients receiving daratumumab and their presentation to the transfusion laboratory by looking at the different pre-transfusion policies and the risk of erythrocyte alloimmunization. Patients receiving daratumumab from 2018 to 2023 were reviewed. They were divided into two groups: Group I, presented before administration of daratumumab, and Group II, presented after drug administration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!